Keywords: claritin, switch, hits, s-p, sales, down, usa-based
Claritin switch hits S-P, sales down 4% in 2002
Article | 03 February 2003
USA-based Schering-Plough says that, for the fourth quarter endedDecember 31, 2002, it tripled its net income from $143 million in the like, year-earlier ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
